Thioridazine: a selective inhibitor of peroxisomal beta-oxidation in vivo.
In vivo administration of the phenothiazine drug, thioridazine, inhibits hepatic peroxisomal beta-oxidation in mice. In starving animals, 3-hydroxybutyrate concentration is not decreased by thioridazine treatment. These results provide the first demonstration of thioridazine as a selective inhibitor of peroxisomal beta-oxidation in intact animals. Thioridazine might supply a tool for simulation of pathological conditions in which peroxisomal beta-oxidation is impaired.
D020155:3-Hydroxybutyric Acid; D000818:Animals; D002374:Catalase / Q000378:metabolism; D005227:Fatty Acids / Q000378:metabolism*; D006861:Hydrogen Peroxide / Q000378:metabolism; D006885:Hydroxybutyrates / Q000097:blood; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008830:Microbodies / Q000187:drug effects* / Q000378:metabolism; D013881:Thioridazine / Q000494:pharmacology*
D005227:Fatty Acids; D006885:Hydroxybutyrates; D006861:Hydrogen Peroxide; D002374:Catalase; D013881:Thioridazine; D020155:3-Hydroxybutyric Acid